A new report on Crestor is raising safety concerns AGAIN
July 2005
A new report on Crestor is raising safety concerns AGAIN.
This analysis suggests a trend towards more cases of severe myopathy and a higher rate of proteinuria with Crestor.
The FDA looked at this data previously...and decided to leave Crestor on the market for now. They say the incidence of side effects with Crestor is similar to that of the other statins.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote